zuclopenthixol acetate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
zuclopenthixol acetate: clinical details
Prescribing considerations
- Confirm that an intermediate-acting acetate injection is appropriate for initial treatment rather than immediate rapid tranquillisation or maintenance therapy.
- Review cardiac disease, rhythm history, electrolyte disturbance, epilepsy, Parkinson's disease, organ impairment, diabetes, stroke and venous-thromboembolism risks.
- Avoid concurrent antipsychotics and review sedative, QT-prolonging, electrolyte-depleting and CYP2D6-inhibiting medicines.
- Older people require close supervision because sedation, hypotension, confusion and impaired temperature regulation are more likely.
- It is not recommended for children because clinical experience is lacking, and it is not licensed for dementia-related behavioural disturbance.
Contraindications and cautions
- Hypersensitivity to zuclopenthixol or an excipient
- Circulatory collapse
- Depressed consciousness from any cause, including alcohol, opioid or barbiturate intoxication
- Coma
Monitoring
- Assess alertness, blood pressure, movement symptoms and swallowing after administration.
- Evaluate cardiovascular and electrolyte risks; use ECG assessment where clinically indicated.
- Identify venous-thromboembolism risk factors before and during treatment.
- Monitor glucose control in people with diabetes.
- Check blood counts if persistent infection develops.
- Consider liver-function and serum-level assessment in hepatic impairment.
Clinical pharmacology
Zuclopenthixol is a potent thioxanthene antipsychotic with dopamine D1- and D2-receptor antagonism. Esterification with acetate increases lipid solubility; after oil-based intramuscular injection, enzymatic hydrolysis gradually releases active zuclopenthixol.
Formulation and product differences
- Zuclopenthixol acetate is an oily, intermediate-acting intramuscular formulation used for initial treatment; it is not the same as oral zuclopenthixol dihydrochloride or long-acting zuclopenthixol decanoate depot injections.
- It may be mixed in the same syringe with other products in the Clopixol injection range, but not with other injection fluids.
zuclopenthixol acetate interactions
Important interactions include:
Alcohol, barbiturates and other central nervous system depressants
May produce greater sedation and impaired alertness.
Medicines that prolong the QT interval
Antiarrhythmics, certain antibiotics, antihistamines and other antipsychotics may add to the risk of dangerous heart rhythms and should generally be avoided.
Thiazide diuretics and other medicines causing low potassium or magnesium
Electrolyte disturbance can increase the risk of QT prolongation and arrhythmia.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.